SSY Group (HK:2005) has released an update.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Phenylephrine Hydrochloride Injection, a drug used to maintain blood pressure and control certain heart conditions. This approval marks a significant step in the Group’s product development strategy, potentially boosting its market presence and appeal to investors.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.
